The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 6, 2024.
HWM, LGND, MATX, SMFKY and HAE have been added to the Zacks Rank #1 (Strong Buy) List on June 6, 2024.
Listening to the Zacks Rank can consistently result in market-beating gains, as positive earnings estimate revisions provide the fuel needed for shares to move higher.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.
MNSO, LSPD and HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 28, 2023.
Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?